格隆汇12月16日丨金斯瑞生物科技(01548.HK)发布公告，2025年12月15日，公司向两名董事授出合共 36,314股股份奖励，惟待接纳及须遵守2019年限制性股份单位计划的条款及条件。其中，(a)18,157股限 制性股份单位被授予公司独立非执行董事John Quelch博士；及(b)18,157股限制性股份单位被授予公司独 立非执行董事Ross Grossman博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 授出股份獎勵 本公告由本公司董事會根據上市規則17.06A條、17.06B條及17.06C條作出。除本公告另 有界定者外，本公告所用專有詞彙與通函所界定者具有相同涵義。 授予A的日期： 2025年12月15日 授出股份獎勵數目： 36,314股限制性股份單位 董事承授人： (a) 18,157股限制性股份單位被授予本公司獨立非執行董事 John Quelch博士；及 (b) 18,157股限制性股份單位被授予本公司獨立非執行董事 Ross Grossman博士。 股份市價： 於授予A的日期，股份於聯交所的收市價為每股股份12.86港 元。 歸屬期： 根據授予A及2019年限制性股份單位計劃的條款，授予董事 承授人的限制性股份單位將在合共約3年的歸屬期（即從授 予A的日期至最後歸屬日期期間 ...

發行人剛在本網站英文版面發布一項公告，相應中文版本或會／或不會在本版面發布。 ...

發行人剛在本網站英文版面發布一項公告，相應中文版本或會／或不會在本版面發布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 修訂2019年限制性股份單位計劃 及2021年限制性股份單位計劃 兹提述本公司日期為2024年4月22日的通函，關於（其中包括）採納經修訂的2019年限 制性股份單位計劃及經修訂的2021年限制性股份單位計劃。除本公告另有界定者外，本 公告所用專有詞彙與通函所界定者具有相同涵義。 董事會欣然宣佈，其決議對2019年限制性股份單位計劃及2021年限制性股份單位計劃作 出如下修訂： 對2019年限制性股份單位計劃的修訂 | 條款 | 修訂 | | --- | --- | | 6.3 | 對於非美國參與者的選定參與者，限制性股份本公司依據限制性股份單位 | | | 發行股份的義務可通過以下任一方式履行：(i)由本公司或受託人在市場上 | | | 回購現有股份；(ii)使用經授權但未發行的股份、 ...

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

每经AI快讯，金斯瑞生物科技(01548.HK)午后跌幅扩大逾11%，截至发稿跌11.07%，报13.41港元，成 交额3.07亿港元。 ...

Core Viewpoint - Kingsray Biotechnology (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a total sales revenue of USD 1.332 billion for the first three quarters, with Q3 sales reaching USD 524 million [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, indicating a substantial reduction in losses year-on-year and quarter-on-quarter [1] - Huatai Securities previously noted that Legend Biotech's losses are narrowing and the group's strategic vision is clear, suggesting a positive outlook for Kingsray Biotechnology's various business segments to achieve orderly profit growth and turnaround [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for its next-generation CAR-T therapy, anito-cel, at the 2025 American Society of Hematology (ASH) annual meeting, showing a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1]

Core Viewpoint - Kingsoft Biotech (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a narrowed loss, with a clear growth blueprint, achieving sales of USD 1.332 billion for the first three quarters, including USD 524 million in Q3 [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, showing significant year-on-year and quarter-on-quarter improvement [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for the next-generation CAR-T therapy anito-cel at the 2025 American Society of Hematology (ASH) annual meeting, demonstrating a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1] - The positive clinical results for anito-cel may impact the market perception of Kingsoft Biotech and its affiliate, as they compete in the CAR-T therapy space [1]

金斯瑞生物科技(01548)发布公告，传奇生物科技股份有限公司("传奇"，为公司联营公司，其股份以美 国存托股份形式于美国纳斯达克全球精选市场上市)于2025年12月6日(纽约时间)发布新闻稿宣布于2025 年美国血液学会("美国血液学会")年会上通过一项口头报告公布了CARVYKTI(西达基奥仑赛，cilta-cel) 在复发或难治性多发性骨髓瘤(RRMM)患者中开展的CARTITUDE-1和CARTITUDE-4研究长期随访的临 床及转化研究数据， 以及III期研究CARTITUDE-4的最新结果，还通过六项壁报展示了CARVYKTI在不同亚组中的缓解持久 性数据及真实世界研究结果。传奇亦在美国血液学会年会通过口头报告展示了双靶点同种异体CAR-T候 选产品LUCAR-G39D的首次人体试验数据。 ...